CVS Health Doubled Operating Profit, but Costs Still Loom

The headline change was not the 7.3% increase in revenue to $106.10 billion. It was the conversion of that growth into profit. GAAP operating income rose 97.5% to $4.70 billion, lifting the operating margin to 4.4% from 2.4% one year earlier. GAAP diluted EPS increased to $2.31 from $0.80, while adjusted EPS rose to $2.58 from $1.81. Adjusted operating income increased 35.4% to $5.16 billion, showing that the improvement extended beyond the absence of prior-year charges, according to the CVS Health Q2 2026 earnings release.

Health Care Benefits, which includes Aetna, supplied most of the earnings improvement. Segment revenue increased 3.5% to $37.54 billion, but adjusted operating income rose 85.5% to $2.43 billion. The medical benefit ratio fell to 87.4% from 89.9%, a 250-basis-point improvement. Management attributed this to better underlying performance in the Government business and the absence of a $471 million premium deficiency reserve recorded in the prior-year quarter. Medical membership was stable sequentially at 26.0 million but declined from 26.7 million a year earlier, partly reflecting the exit from the individual exchange business.

The pharmacy businesses improved, although their revenue and profit patterns differed. Health Services revenue rose 11.5% to $51.80 billion, driven primarily by pharmacy drug mix and brand inflation. Adjusted operating income increased 10.0% to $1.73 billion, while claims volume advanced only 0.9%. Pharmacy Consumer Wellness revenue increased just 0.7% to $33.82 billion, but adjusted operating income rose 10.2% to $1.48 billion. Prescriptions filled increased 4.3%, helped by Rite Aid prescription-file acquisitions and higher utilization. Reimbursement pressure and regulatory price reductions remained offsets.

Cash generation strengthened materially. The supplied quarterly table shows free cash flow of $5.65 billion, compared with $1.29 billion in Q2 FY2025. For the first half, operating cash flow reached $10.59 billion and capital expenditure was $1.54 billion. CVS used $3.29 billion to repay long-term debt during the first six months, while cash and cash equivalents increased to $11.33 billion at June 30, as reported in the CVS Health Q2 2026 Form 10-Q.

The quarter strengthens the central turnaround case: Health Care Benefits is recovering faster than the prior-year income statement implied. CVS raised full-year GAAP diluted EPS guidance to $6.84-$7.04 from $6.24-$6.44 and adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50. Both midpoints increased by $0.60 per share. Management also raised operating cash flow guidance to at least $11.5 billion from at least $9.5 billion. These are meaningful changes because they improve both the earnings base and CVS’s capacity to reduce leverage.

The quality of the comparison nevertheless requires care. Of the $2.32 billion year-over-year increase in GAAP operating income, $833 million reflected the absence of legacy litigation charges recorded in Q2 FY2025. Health Care Benefits also benefited from the absence of the $471 million prior-year premium deficiency reserve. Those items do not invalidate the recovery—adjusted operating income still increased by $1.35 billion—but they mean the 97.5% GAAP operating-income growth rate overstates the underlying run-rate improvement.

The more durable evidence is the 250-basis-point reduction in the medical benefit ratio and the 85.5% increase in Health Care Benefits adjusted operating income. Even here, the durability is not settled. Prior-year health-care-cost payable estimates developed favorably by $1.2 billion during the first half, while days claims payable decreased to 41.7 from 42.9 sequentially. Reserve development can support reported results without necessarily describing future claims economics. Management consequently retained what it called a cautious view because of continued elevated cost trends and possible macroeconomic headwinds.

The other segments provide useful diversification but not a complete hedge. Health Services revenue grew rapidly, yet adjusted operating margin slipped to 3.3% from 3.4% as client price improvements offset some of the benefit from purchasing economics and drug mix. Retail pharmacy delivered better gross and operating economics, but revenue growth was modest and reimbursement pressure persisted. The print therefore moves the thesis from uncertain stabilization toward demonstrated recovery, not toward a fully de-risked compounder.

With no prior SageNoodle coverage, this update establishes rather than revises fair value. We value CVS using scenario-specific multiples of forward adjusted EPS because management supplied a full-year adjusted EPS range but did not disclose EBITDA guidance. EV/EBITDA is therefore shown as unavailable rather than inferred. The base case uses the $8.00 midpoint of management’s FY2026 adjusted EPS guidance and a 13.0 times multiple, producing fair value of $104 per share.

The 13.0 times base multiple is an assumption, not a disclosed market benchmark. It recognizes the improving insurance margin, broad segment profit growth and stronger cash outlook, while withholding a premium valuation because of elevated medical-cost risk, pharmacy pricing pressure, leverage and low recent returns on invested capital. FY2025 ROIC was 2.6%, and FY2025 net debt was $55.3 billion. Those figures argue against capitalizing one recovery quarter too aggressively.

The bear case assumes adjusted EPS of $7.20, below current guidance, if medical utilization rises again or the Health Care Benefits improvement proves partly reserve-driven. Applying 10.0 times earnings gives $72 per share. The bull case assumes adjusted EPS reaches $9.00 as insurance margins normalize further and pharmacy earnings hold, then applies 15.0 times earnings for $135 per share. Weighting bear, base and bull outcomes at 25%, 50% and 25% produces $103.75, rounded to $104.

At the current price of $95.29, the resulting upside is 9.1%. Under SageNoodle’s valuation rule, that is Fairly Valued because the fair-value premium is below 15%. The 9.6% trailing free-cash-flow yield is supportive, but the 25.1 times trailing GAAP P/E reflects depressed trailing earnings and is less useful than the forward scenario framework during the recovery. The valuation now requires CVS to deliver most of its raised guidance without a renewed medical-cost setback.

The clearest disconfirming signal would be a renewed rise in the Health Care Benefits medical benefit ratio. The current thesis depends on the 87.4% ratio representing genuine pricing and underwriting repair rather than a temporary benefit from comparisons, reserve development or claims timing. Elevated utilization could reduce segment profit quickly because insurance margins are thin relative to premium revenue. Management’s continued caution on medical costs is therefore more important than the raised headline guidance.

A second risk is that pharmacy revenue growth fails to translate into durable margin expansion. Health Services produced 11.5% revenue growth with only 0.9% claims growth, indicating that drug mix and brand inflation contributed more than volume. Continued client price improvements compressed adjusted margin slightly. Pharmacy Consumer Wellness faces reimbursement pressure, regulatory price reductions and generic introductions even as prescription volume grows. If those pressures intensify, pharmacy earnings may not provide the diversification assumed in the base case.

Leverage narrows the margin for error. The latest supplied XBRL points show $63.71 billion of debt and $11.33 billion of cash. First-half debt repayment was constructive, but the balance sheet remains substantial relative to the company’s 2.6% FY2025 ROIC. A medical-cost reversal combined with weaker cash conversion could slow deleveraging and justify a lower earnings multiple.

Finally, the valuation itself could be wrong even if guidance is achieved. The base case applies 13.0 times adjusted EPS, while adjusted earnings exclude intangible amortization and selected costs. If those exclusions remain recurring economic burdens, GAAP earnings and free cash flow deserve greater weight and the appropriate multiple would be lower. Conversely, sustained medical-margin improvement, continued debt reduction and adjusted EPS above $8.00 would make the bull case more credible. The next print must show that this quarter’s improvement can persist without relying on absent prior-year charges.